AstraZeneca To Initiate Phase-IIb Study For AZD3480
Company also plans to continue development of AZD1446 for Alzheimer’s disease
AstraZeneca is likely to conduct further development of AZD3480, by initiating phase IIb studies in attention deficit/hyperactivity disorder (ADHD). It has agreed to make a $10 million milestone payment to Targacept.
AstraZeneca also plans to continue development of AZD1446 (TC-6683) for Alzheimer’s disease. AZD1446 is currently in phase-I, and was discovered in the ongoing AstraZeneca-Targacept research collaboration.
The company has prioritized the development of AZD1446 over further development of AZD3480. AZD3480 and AZD1446 are selective alpha4beta2 NNR agonists.
AstraZeneca is engaged in the research, development, manufacturing and marketing of prescription medicines. The company is focused on gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.
Related Insight
Suppliers Directory
FOCUS Clinical Drug Development - Exploratory Drug Development of NCEs / NBEs
FOCUS Clinical Drug Development is an independent full-service CRO specialised in early clinical development and integrated proof of concept (PoC) packages. FOCUS has conducted more than 600 high-quality early-phase clinical studies in healthy volunteers and many patient populations.
Suppliers
Lonza Custom Manufacturing - Bioresearch Products, Development Services and Manufacturing for Functional and Active Ingredients
Lonza Custom Manufacturing offers the life sciences market a full range of bioresearch products, flexible development services and high-quality manufacturing for functional and active ingredients.
Suppliers
GE Healthcare Imanet – An Imaging Solutions Business
GE Healthcare Imanet is an imaging solutions business, who's core focus has been conducting exploratory phase positron emission tomography (PET) imaging studies to aid in drug development for the pharma industry since 2001.
Suppliers
Sofus Consulting - Regulatory Affairs, Pharmacovigilance and Quality Assurance
Since 2002, we have specialised in regulatory affairs, pharmacovigilance and quality assurance in pharmaceuticals.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
An Interview with Paul Gerteis
Published by Gerteis
White Papers
Managing Primary IND Applications with the FDA
Published by Celerion
White Papers
Introducing the DAI Auto-Injector
Published by SHL Group (Scandinavian Health Group Ltd.)
White Papers
The Devil is in the Detail!
Published by Vaisala
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.